

Autophagy-Targeting Chimeras: A Revolutionary Approach in Targeted Protein Degradation

Jing Yang*

Department of Otolaryngology-Head and Neck Surgery, College of Medicine, China

Introduction

In the rapidly evolving field of drug discovery, targeted protein degradation (TPD) has emerged as a cutting-edge strategy that offers new opportunities for treating diseases previously considered “undruggable.” One of the most exciting advancements in this field is the development of autophagy-targeting chimeras (ATTEs), a novel class of bifunctional molecules [1] designed to exploit the autophagy-lysosome pathway for protein degradation. These chimeras promise to revolutionize therapeutic approaches by selectively targeting and degrading disease-causing proteins. This article explores the concept of autophagy-targeting chimeras, their mechanisms, applications, and the future potential they hold in drug discovery and disease treatment.

What Are Autophagy-Targeting Chimeras (ATTEs)?

Autophagy-targeting chimeras (ATTEs) are a subclass of targeted protein degraders that use the autophagy-lysosome system to selectively degrade specific proteins. Autophagy is a cellular process responsible for the degradation and recycling of damaged or unnecessary proteins and organelles. Unlike other degradation pathways, such as the proteasome [2] system, autophagy primarily handles larger substrates, including protein aggregates and damaged organelles.

ATTEs are designed to harness the autophagic machinery by linking two key elements:

Targeting ligand: A small molecule or peptide that binds specifically to the protein of interest. This ligand is designed to recognize and selectively bind to the disease-associated protein or any protein that the researcher wants to degrade.

Autophagy recruitment moiety: This part of the chimera binds to autophagy-related proteins, such as sequestosome 1 (p62) or LC3, which are key components of the autophagy machinery [3]. By linking the targeting ligand to the autophagy recruitment moiety, the chimera directs the target protein to the autophagic machinery for degradation.

Once the chimera binds to the target protein and recruits it to the autophagy machinery, the complex is internalized into autophagosomes—vesicles that encapsulate the target protein and eventually fuse with lysosomes, where degradation occurs. This process effectively clears the protein from the cell, offering a unique method for targeted protein removal.

Mechanisms of Action

The mechanism behind ATTEs relies on their ability to induce selective autophagic degradation. Autophagy is a tightly regulated process in cells [4], where damaged or unnecessary proteins are engulfed by autophagosomes, which then fuse with lysosomes to degrade their contents. The autophagy process is triggered by the recognition of specific degradation signals, and this is where ATTEs come into play.

Binding to the target protein: The targeting ligand of the ATTE binds to the protein of interest, bringing it into close proximity to the autophagy machinery.

Recruitment to autophagy machinery: The autophagy recruitment moiety within the chimera interacts with autophagy-related proteins, such as p62. p62 is a protein that serves as an adaptor, bridging the target protein and the autophagy machinery [5]. This recruitment step ensures that the protein is tagged for degradation by the autophagy-lysosome pathway.

Formation of autophagosomes: Once the target protein is recruited to the autophagic machinery, it is encapsulated within an autophagosome—a double-membraned vesicle that transports cellular material to the lysosome for degradation.

Degradation: The autophagosome fuses with the lysosome, where the acidic environment and hydrolases degrade the target protein, breaking it down into smaller peptides or amino acids for recycling. This process clears the target protein from the cell, thereby reducing its potential to cause disease [6].

Applications of Autophagy-Targeting Chimeras

Autophagy-targeting chimeras have the potential to be applied across a wide range of therapeutic areas, especially in diseases driven by the accumulation of toxic proteins. Some of the most promising applications include:

Cancer therapy: Many cancers are driven by the overexpression or accumulation of oncogenic proteins, such as mutant p53 or MYC. ATTEs can be used to selectively degrade these proteins, inhibiting tumor growth and progression. Furthermore, autophagy has been implicated in cancer cell survival under stress conditions, so manipulating this pathway could help overcome resistance to traditional therapies.

Neurodegenerative diseases: In diseases like Alzheimer's, Parkinson's, and Huntington's, the accumulation of misfolded or aggregated proteins—such as amyloid-beta, tau, or alpha-synuclein—is a hallmark feature. ATTEs could help clear these toxic proteins from neurons [7] by directing them to the autophagy-lysosome system, potentially slowing disease progression and improving symptoms.

Metabolic disorders: Autophagy plays a critical role in maintaining cellular homeostasis by clearing damaged organelles and proteins. By targeting metabolic proteins for degradation, ATTEs could be used to treat metabolic diseases such as obesity, type 2 diabetes, and lipid

***Corresponding author:** Jing Yang, Department of Otolaryngology-Head and Neck Surgery, College of Medicine, China, E-mail: jing_y@gmail.com

Received: 01-Feb-2025, Manuscript No: jcmp-25-162172, **Editor Assigned:** 03-Feb-2025, pre QC No: jcmp-25-162172 (PQ), **Reviewed:** 16-Feb-2025, QC No: jcmp-25-162172, **Revised:** 21-Feb-2025, Manuscript No: jcmp-25-162172 (R), **Published:** 28-Feb-2025; DOI: 10.4172/jcmp.1000256

Citation: Jing Y (2025) Autophagy-Targeting Chimeras: A Revolutionary Approach in Targeted Protein Degradation. J Cell Mol Pharmacol 9: 256.

Copyright: © 2025 Jing Y. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

storage diseases.

Targeting “Undruggable” proteins: Many disease-associated proteins are considered “undruggable” because they lack suitable binding sites for small molecules or antibodies. ATTEs offer a solution by targeting these proteins for degradation, bypassing the need for traditional inhibitors. This approach opens up new therapeutic opportunities for treating diseases that were previously difficult to target with conventional methods.

Autoimmune diseases: In autoimmune diseases, abnormal protein accumulation or dysregulated protein functions can lead to inflammation and tissue damage. By using ATTEs to degrade specific proteins involved in the immune response, it may be possible to modulate immune function and alleviate symptoms [8].

Advantages of Autophagy-Targeting Chimeras

Selective protein degradation: ATTEs offer a high level of selectivity, allowing researchers and clinicians to target specific proteins without affecting the rest of the proteome. This selectivity minimizes potential side effects and ensures that only the disease-causing proteins are degraded.

Targeting “Undruggable” proteins: The unique ability of ATTEs to degrade proteins that are difficult to target with traditional small molecules provides an opportunity to treat diseases driven by proteins that are otherwise resistant to conventional drug development efforts [9].

Autophagy pathway utilization: By leveraging the autophagy pathway, ATTEs provide an alternative to proteasomal degradation, which may be particularly useful for larger proteins, aggregates, or damaged organelles that are not efficiently degraded by the proteasome.

Reversible control: ATTEs can be designed to work in a reversible manner, allowing for tight control over the degradation process. This makes them valuable tools for both therapeutic applications and research studies, where temporal control over protein levels is crucial.

Challenges and Future Directions

Despite the potential of ATTEs, several challenges remain:

Optimization of chimeras: The design of ATTEs must balance the affinity of the targeting ligand, the autophagy recruitment moiety, and the linker to ensure efficient and specific protein degradation. Optimizing these components is essential for achieving maximal therapeutic efficacy.

Delivery and tissue-specific targeting: Efficient delivery of ATTEs to the target tissues and cells is crucial. While systemic delivery of small molecules is often challenging [10], developing targeted delivery strategies (e.g., using nanoparticles or cell-specific carriers) will enhance the therapeutic potential of ATTEs.

Long-term safety: As with any new therapeutic modality, the long-term safety of ATTEs must be evaluated. Ensuring that the selective degradation of proteins does not disrupt essential cellular functions or lead to toxicity is essential for their safe use in humans.

Resistance mechanisms: Just as resistance mechanisms can develop in response to traditional therapies, cells may develop ways to circumvent the action of ATTEs. Ongoing research will be necessary to understand and overcome potential resistance mechanisms.

Conclusion

Autophagy-targeting chimeras represent a promising new approach in the field of targeted protein degradation, offering a unique method for selectively removing disease-causing proteins through the autophagy-lysosome pathway. With applications spanning cancer, neurodegenerative diseases, metabolic disorders, and beyond, ATTEs hold the potential to revolutionize the treatment of a wide range of diseases. Although challenges such as optimization, delivery, and safety remain, the future of ATTEs in drug discovery and personalized medicine is incredibly promising. As research in this area continues to advance, autophagy-targeting chimeras may become a key tool in the fight against diseases previously deemed untreatable.

References

1. Mujeeb F, Bajpai P, Pathak N (2014) Phytochemical evaluation, antimicrobial activity, and determination of bioactive components from leaves of *Aegle marmelos*. *BioMed Res Int* 2014: 497606.
2. Li J, Lu C, Jiang M, Niu X, Guo H, et al. (2012) Traditional chinese medicine-based network pharmacology could lead to new multicomponent drug discovery. *Evid Based Complement Alternat Med*.
3. Yuan H, Ma Q, Ye L, Piao G (2016) The Traditional Medicine and Modern Medicine from Natural Products 21: 559.
4. Pan SY, Chen SB, Dong HG, Yu ZL, Dong JC, et al. (2011) New perspectives on chinese herbal medicine (zhong-yao) research and development. *Evid Based Complement Alternat Med* 2011: 403709.
5. Velmurugan BK, Rathinasamy B, Lohanathan BP, Thiyagarajan V, Weng CF (2018) Neuroprotective Role of Phytochemicals. 23: 2485.
6. Leung DW, Cachianes G, Kuang WJ (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. *Science* 246: 1306-1309.
7. Olofsson B, Pajusola K, Kaipainen A (1996) Vascular endothelial growth factor B, a novel growth factor for endothelial cells. *Proc Natl Acad Sci USA* 93: 2576-2581.
8. Joukov V, Pajusola K, Kaipainen A, Chilov D (1996) novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. *EMBO J* 15: 290-298.
9. Yamada Y, Nezu J, Shimane M (1997) Molecular cloning of a novel vascular endothelial growth factor. *VEGF DGenomics* 42: 483-488
10. Olsson AK, Dimberg A, Kreuger J (2006) VEGF receptor signalling in control of vascular function. *Nat Rev Mol Cell Biol* 7: 359-371.